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ABSTRACT
Introduction: Psoriasis is a chronic disease,
which contributes to the economic burden on
health care. The distribution of psoriasis
medication costs and the quality of life in
these patients has been estimated to be around
20% of total costs.
Objectives: To estimate the economic
distribution of medications and the impact of
multiple treatment options on a patient’s
quality of life.
Materials and methods: The study was based
on 236 Finnish psoriasis patients. The Finnish
Social Insurance Institution had databases for
all psoriasis related medications purchased.
Each purchase, during the 1-year study period
(1 October 2009–30 September 2010), was
recorded and analyzed. The dermatological
quality-of-life index was collected from the
medical records.
Results: Total medication costs were €1,083 per
year per patient. Topical treatments were the most
often purchased medication and they comprised
18% of the total medication costs. Ten percent of
the patients needed 3 or more medication
changes during the 1-year study period.
Biologics were used only by 5% of patients, but
they produced 67% of total medication costs.
Patients needing various treatments had higher
medication costs and a poorer quality of life.
Conclusion: A small number of patients
generated a great sum of medication costs
partly due to the need to change medications.
These patients had the worst quality-of-life
index scores. Biologics formed a major cost
component.
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version of this article (doi:10.1007/s13555-013-0040-z)
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INTRODUCTION
Psoriasis (Ps) is a chronic inflammatory disease
with a global prevalence of 1.5–2.8% and
around 6–30% of Ps patients also have
psoriatic arthritis (PsA) [1–5]. Ps is treated with
topical medications—corticosteroids and
vitamin-D analogs, UV-phototherapy, systemic
medications—methotrexate, acitretin and
ciclosporin or with biological medications [6,
7]. Mild Ps is treated with topical medications.
Moderate-to-severe Ps is treated with systemic
medications or UV-phototherapy or with a
combination of both [6, 7]. Use of biologic
medications is recommended as second-line
medications or only when traditional systemic
medications or UV-phototherapy are not
successful [6, 8]. It has been suggested that
patients with severe Ps should be treated more
with systemic medications [9].
In the Finnish health care system, patients
with mild Ps are treated mainly in primary level
health care. Moderate and severe Ps patients are
treated in tertiary or secondary level
dermatological clinics. However, these patients
can also be treated in primary level settings,
particularly if they are responding to the
treatment given. Medication costs are partly
reimbursed to patients by the Finnish Social
Insurer Institute.
Ps is a lifelong disease and leads to a
considerable burden and expenses to health
care [2, 9–14]. The cost-of-illness estimations of
the total costs have a wide range extending
from €1,079 to €8,371 [8–13]. The proportion of
medications costs is approximately 20% of total
costs [10, 13, 15–17]. Biologic medications
increase the total costs and the proportion of
medication costs [18]. Often the estimated
medication costs are based on assumptions
extrapolated from cross-sectional
questionnaire data. There is no previous
information about the medication costs of Ps
in Finland. The costs of all Ps medications, not
just biologics, have been increasing significantly
during the past decade [19]. Treatment failure is
a major factor, which increases the treatment
costs [13, 20]. Advancing from the safest
medication available to more potent
medicines, results in multiple treatment failure
for many patients, as combinations or more
efficient medications are often needed to clear
Ps [20]. Intolerance to a specific medication may
also lead to treatment failure and a decision to
advance to another therapy [20]. Patients failing
to respond to treatments had the highest total
costs [13].
The aim of this study was to estimate the
economic distribution of Ps medications from a
societal perspective and to assess the
dermatological quality of life in Ps patients
needing multiple treatments.
MATERIALS AND METHODS
The sample was based on patients whom had
visited the Department of Dermatology in
Turku University Hospital, Finland, between 1
October 2009 and 30 September 2010. They
were all diagnosed to have Ps or PsA. In the
Finnish health care system, patients with mild
level Ps are treated at primary health care
settings and only moderate-to-severe cases are
referred to tertiary level hospital for further
treatment. A total of 498 patients attended the
clinic during the study period (428 had Ps and
70 had PsA). The patients were sent a
questionnaire by mail. A total of 262 patients
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completed the questionnaire (52.6% of the total
study sample). Patients with Ps or PsA
participated equally [21].
Compliance with Ethics
The ethical committee of The Hospital District
of Southwest Finland approved the study. The
patients received a written description of the
sampling procedure and study purpose, as well
as the planned use and storage of the
information they were to provide. The patients
were asked to give a written consent to use their
medical records for the study.
All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Informed consent was
obtained from all patients for being included
in the study.
Questionnaire
Socio-demographic background was collected
with the questionnaire. The questions included
gender, age, home municipality, number of
persons living in the same household, income
level and disease duration.
Clinical Data
Out of the 262 patients who completed the
questionnaire, 26 patients did not give written
consent for the right to use their medical
records. Clinical information was collected
from the 236 patients’ medical records who
gave consent, for the same time period that was
covered in the questionnaire data. The
information consisted of Psoriasis Area
Severity Index (PASI), Dermatology Life
Quality Index (DLQI), the diagnosis [ICD-10
(International Statistical Classification of
Diseases and Related Health Problems)] and
whether a patient had received UV-
phototherapy during the study period. PASI
describes the patient’s Ps severity and area, and
the PASI values rise with increasing severity.
PASI values are based on a scale from 0 to 72.
Higher DLQI values represent a poor quality of
life. DLQI values are based on a scale from 0 to
30. Laboratory costs were collected with a
separate retrieval from the hospital’s patient
records. They consisted of all the tests (not only
monitoring) ordered by the dermatological
clinic during the study period. Laboratory
costs were from the whole study period and
they could not be linked to a specific
medication causally.
Medication Use
The Finnish Social Insurance Institution (FSII)
reimburses part of a patient’s medicine
expenses. In practice, all Finnish Ps patients
receive reimbursements for all their Ps-related
medications and emollients no matter who
prescribes the medications. FSII provided data
of all Ps-related medication purchases of the
study patients who had given consent. Ps-
related medication in this study comprised all
biologic medications (including adalimumab,
etanercept, infliximab, and ustekinumab),
traditional systemic medications (including
methotrexate, acitretin, and ciclosporin),
topical drugs (including vitamin-D analogs,
corticosteroid creams and combinations of
these), leflunomide, topical fungal medicine,
antihistamines and emollients. All purchases
during the study period between 1 October
2009 and 30 September 2010 were recorded. FSII
records of each purchase contained the total
cost of the medication/emollient and the
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ATC-code (Anatomical Therapeutic Chemical
Classification) of the purchase as well as the
amount of packages purchased. ATC-codes were
used to identify each drug. Drugs were clustered
based on their active ingredients regardless of
their brand names.
Treatment Options
To analyze how many different types of
treatments each patient used, treatment
options were formed as following. All topical
medications (not including emollients) were
pooled as one treatment option. Traditional
systemic medications (methotrexate, acitretin,
and cyclosporine) were analyzed separately and
each of them formed one treatment option. All
biological medications formed one treatment
option. They were pooled because of the low
number of patients using them. UV-
phototherapy was considered as one treatment
option. Emollients, fungal medicines,
antihistamines and other medications, which
might have been used as supportive
medications, were not considered as a separate
treatment option. However, these medications
were included for the total cost computations of
medications.
Medication Costs
The total cost of the drugs was used as the
societal cost in all calculations without any
reimbursement deductions. All medication
costs were analyzed for the annual cost of
medications per patient. Only the drugs in
each treatment option were included for the
cost calculations, when analyzing the costs of
different treatment options. UV-phototherapy’s
costs were not considered in any of the cost
analyses.
Statistical Analysis
In the analyses of the subgroup with PASI and
DLQI values, all patients without recorded PASI
or DLQI values were excluded. If several PASI or
DLQI values were recorded for a patient during
the study period, the arithmetic mean values
were computed and used. When analyzing the
subgroups with recorded PASI values, patients
were divided by the median value into more
severe (PASI[5.5, n = 37) and less severe
psoriasis (PASI B 5.5, n = 35). The statistical
evaluation of the data was based on Chi-
square test for proportions and Student’s t test
for means. The distribution of the DLQI values
was skewed and to account for this, a
Spearman’s non-parametric correlation was
used.
RESULTS
Patients in the study sample were on average
57 years old, 55% were male. Fifty percent of
patients were retired, 38% currently working
and 13% unemployed. On average they had had
Ps for 20 years and 14% of patients had PsA. The
mean DLQI score was 11.0 and the mean PASI
score 6.5.
Total medication costs were €1,083 per year
per patient. Topical treatments were most often
purchased medications and they comprised
18% of the total medication costs (Table 1).
Biologics and ciclosporin were the most
expensive medications and were rarely used
(Table 1). Biologics were used only by 5% of the
patients, but they produced 67% of total
medication costs. Methotrexate was used by
18% of patients, yet it produced only 0.6% of all
medication costs. Patients using ciclosporin and
methotrexate had higher laboratory costs than
patients not using them (Table 1).
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UV-phototherapy was a treatment option for
36% of the patients. Out of the study group, 9%
did not receive any treatment option, 29%
received one, 51% two, 9% three and 1% of
the patients received four treatment options
during the 1-year follow-up period. Topical
treatment was most often combined with
other treatment options. Patients receiving
multiple various treatment options had
considerably higher costs than patients
receiving fewer treatment options (Fig. 1), the
differences were significant (p\0.05) among all
three groups. Patients who received more
treatment options during the 1-year follow-up
period had a significantly (p\0.05) lower
quality of life measured with DLQI (r = 0.384)
(Fig. 2). PASI scores did not correlate with the
number of different treatments. Patients not
receiving any kind of treatment were more
likely to be unemployed (p\0.05), irrespective
of level of income.
Patients with more severe Ps (n = 35) had
higher total medication costs (€2,559) than
patients (n = 37) with less severe Ps (€1,375)
(p\0.05). When each treatment option was
analyzed separately, only the costs of topical
medications was significantly (p\0.05) higher
for those with more severe psoriasis (€394) than
patients with less severe Ps (€163). There was no
significant difference in the probability of
receiving topical treatments between the two
groups, but there was a significant (p\0.001)
difference in the total number of packages of
topical medications bought between less (mean
2.4 packages/year) and more severe (8.7 packages/
year) Ps patients. Methotrexate, ciclosporin and
biologic medications formed higher statistically
Table 1 The cost-of-treatment options (not including other psoriasis-related medications or emollients) and laboratory
tests for patients receiving each medication and the proportion of the patients who had received each medication




Acitretin 351 (n = 46) 20 63
Ciclosporin 1,420 (n = 3) 1 213
Methotrexate 39 (n = 43) 18 124*
Biologics 15,630 (n = 11) 5 58
Topical treatments 242 (n = 194) 83 57*
* p\0.05 signiﬁcantly higher than patients not receiving the medication
Fig. 1 The average costs of all medications and emollients
as a function of the number of treatment options (only
acitretin, ciclosporin, methotrexate, biologics, topical treat-
ments and UV-phototherapy) received during the 1-year
study period. The number of treatment options represents
the number of different medications or UV therapy
administered to the patient, with the percentage of patients
in each group in parenthesis. Differences between all
treatment groups were statistically signiﬁcant (p\0.05)
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non-significant (NS) (p = 0.19–0.5) medications
costs for patients with more severe Ps. There was
no statistically significant difference in the rate of
acitretin prescriptions for participants between
different severity groups.
Men and women had equal probability to
receive topical medications. However, among
those using them, men used more and this led
to significantly (p\0.05) higher costs (€299) for
men than women (€171). Biologics and
ciclosporin were only purchased by Ps
patients, thus producing higher (NS,
p = 0.1–0.2) total costs of medications for Ps
patients (€1,331) than PsA patients (€316).
DISCUSSION
The results of this study may indicate that
treatment failure or not finding an effective
treatment for a Ps patient produces a significant
increase in medication costs and a higher DLQI
score. Medication costs can be excluded as a
cause for the higher DLQI score because in
Finland, social insurance limits expenses. This
strongly suggests that treatment failure could
lead to a Ps patient’s decreased quality of life.
In this study, UV-phototherapy costs were
not included in medication cost computations.
However, if a patient had received UV-
phototherapy, they had a higher probability to
have received multiple treatment options. This
indicates that the higher the number of
treatment options contributes to a higher cost
to the patients. Prior studies have suggested that
treatment failure was likely for patients
receiving systemic therapies or UV-
phototherapy and it produces high costs in Ps
treatment [20, 22]. Our study results are in line
with those studies.
Dermatology Life Quality Index may be a
better index to predict higher costs than PASI in
patients needing multiple treatment options. A
recent study by Ekelund et al. [16] estimated
that high DLQI scores are associated with high
medication costs. In this study, PASI scores were
not significantly associated with medication
costs. Staidle et al. [23] suggest that DLQI or
other methods of measuring a patient’s quality
of life should be integrated in cost-analysis of
medications and treatments. However, PASI
values predicted the quantities of medications
used better than DLQI. The number of patient
records available in this study, which had PASI
or DLQI index scores, was limited, which may
be a source of selection bias. These findings
should be considered cautiously and further
studies are warranted. In this sample, only few
patients had PASI values above 10, and using
such high index value for categorizing would
have produced a subgroup of severe Ps patients
which is too small for statistical analyses. Owing
to this the subgroups were defined as less and
more severe psoriasis patients, instead of calling
them moderate and severe.
In prior studies, annual costs of medications
per psoriasis patient vary from €107 to €3,132
Fig. 2 Dermatological Life Quality index (DLQI) values
increased by the number of treatment options to the
patient during the 1-year study period. A signiﬁcant
(p\0.05) correlation (r = 0.384) existed between DLQI
and the number of treatment options
174 Dermatol Ther (Heidelb) (2013) 3:169–177
123
[10, 13, 15, 17, 24, 25]. Our results are similar to
a study by Berger et al. [15] and Colombo et al.
[10] with costs in the middle of the range. In the
study by Augustin et al. [24] where the costs
were €107 per patient, the sample comprised
general Ps patients, thus a majority of patients
had mild Ps unlike most other studies, resulting
in lower medication costs. In Sohn et al.’s [13]
study, a strict inclusion criterion led to a study
sample with very severe psoriasis with a mean
PASI of 18.2 and high medication costs of
€2,014 per year. A higher proportion of the
study population using biologic medications
increased the overall medications costs
significantly. In Ghatnekar et al.’s [17] study,
biologic medications were received by 16% of
patients and the costs for biologics were, for the
entire population, on average €2,386 per patient
per year. In our study, the costs for all
medications were significantly lower, partly
due to the lower number of patients receiving
biologics.
Here, the proportion of biologics prescribed
was low when compared to other studies [17,
26, 27]. None of the PsA patients received
biologics. Some PsA patients might have been
treated by rheumatologists instead of
dermatologists and thus, such patients were
not selected. However, the findings in this study
indicate that biologics should be considered
more often for patients that have failed to
respond to other systemic medications, as they
had considerably lower quality-of-life indices.
Some studies [6] suggest that biologics should
be used only if traditional systemic therapies
have proven ineffective or have produced side
effects, but other studies [8] suggest that
biologics should be considered as second-line
treatment if UV-phototherapy is not effective
enough for severe psoriasis patients due to
biologics good safety profile and effectiveness.
Increasing the number of patients receiving
biologics increases the costs of medication
dramatically [19, 28]. Our findings are in line
with the results of Beyer et al. [19]. As in our
study, the patients that received biologic
medications had ten times higher medication
costs than patients that received traditional
systemic or topical treatments.
Although almost every fifth patient had
purchased methotrexate during the follow-up
period, their costs to the society were marginal.
Laboratory and outpatients costs are higher for
patients using methotrexate because of the
required regular laboratory tests and possible
need for liver biopsies [6, 8]. The adverse effects
of drugs are difficult to incorporate in cost
comparison studies, but they play a significant
role in decision-making of clinical practice [8].
In this study, laboratory costs were also higher
for patients receiving methotrexate than other
patients, but our data allowed only indicative
estimations as causality of laboratory costs with
specific medications could not be formed.
Present study data were collected from the
Hospital District of Southwest Finland only.
However, the findings should be generalizable
for the whole of Finland, as there is no reason to
assume that Ps patients in various parts of the
country would be different. Furthermore,
clinical treatment guidelines are common
throughout the country.
CONCLUSION
Patients needing multiple different treatments
generate high costs and have worse quality of
life. A small number of patients generate the
majority of medication costs. Although
biologics are expensive, these hold potential to
improve the quality of life in patients with
severe Ps.
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